UPDATE TO THE LONG-TERM SAFETY AND EFFICACY OF IPTACOPAN IN C3G: 33-MONTH EXTENSION STUDY DATA FROM PATIENTS ENROLLED IN A PHASE 2 STUDY

  Back
UPDATE TO THE LONG-TERM SAFETY AND EFFICACY OF IPTACOPAN IN C3G: 33-MONTH EXTENSION STUDY DATA FROM PATIENTS ENROLLED IN A PHASE 2 STUDY
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than January 23, 2025. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/cf5b06d6edff1d7791b404cfa9be2035.pdf
Carla
Nester
11
Ute Eisenberger ute.eisenberger@uk-essen.de University Hospital, University of Duisburg-Essen Department of Nephrology Essen Germany
Alexandre Karras alexandre.karras@aphp.fr Hôpital Européen Georges Pompidou Service de Néphrologie Paris France
Moglie Le Quintrec m-lequintrec-donnette@chu-montpellier.fr Centre Hospitalier Universitaire de Montpellier Service de Néphrologie et Transplantation Rénale Montpellier France
Liz Lightstone l.lightstone@imperial.ac.uk Centre for Inflammatory Disease, Imperial College London Department of Immunology and Inflammation London United Kingdom
Manuel Praga mpragat@senefro.org Complutense University Department of Medicine Madrid Spain
Giuseppe Remuzzi giuseppe.remuzzi@marionegri.it Mario Negri IRCCS Istituto di Ricerche Farmacologiche Bergamo Italy
Maria José Soler mariajose.soler@vallhebron.cat Hospital Universitari Vall d’Hebron Nephrology Department Barcelona Spain
Junhao Liu junhao-1.liu@novartis.com Novartis Pharmaceuticals Corporation Global Drug Development East Hanover United States
Matthias Meier matthias.meier@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland
Nicholas JA Webb nicholas.webb@novartis.com Novartis Pharma AG Global Drug Development Basel Switzerland
Edwin KS Wong Edwin.wong1@nhs.net Royal Victoria Infirmary National Renal Complement Therapeutics Centre Newcastle upon Tyne United Kingdom